NSE
Lupin LimitedLUPIN
Lupin is a major pharma company strong in US generics and respiratory.
| Key products | Generics, inhalation, biosimilars, APIs; India branded. |
|---|---|
| Geography | US, India, EMEA, APAC. |
| Competitors | Sun Pharma, Cipla, Dr Reddy's. |
AI-generated overview — verify before relying on it.
Net institutional flow
No institutional deals
Institutional buyers
0 in / 0 out
High-impact filings
0 · tilt Neutral
Next corporate action
Dividend - Rs 12 Per Share
ex 2025-07-25
| # | Company | Inst. flow ₹Cr | Deals | Hi-impact | Filing mom. | Buzz | News |
|---|---|---|---|---|---|---|---|
| 1 | ALKEM | +₹1,013.7 Cr | 13 | — | — | -2 | 6 |
| 2 | LUPINThis | — | — | — | — | — | — |
| 3 | CIPLA | — | — | — | — | +19 | 44 |
| 4 | DRREDDY | — | — | — | — | +20 | 46 |
| 5 | SUNPHARMA | — | — | — | — | +15 | 45 |
| 6 | TORNTPHARM | — | — | — | — | — | — |
| 7 | ZYDUSLIFE | — | — | 1 | +1 | — | — |
| 8 | AUROPHARMA | — | — | — | — | — | — |
| 9 | MANKIND | — | — | — | — | — | — |
Ranked by net institutional flow (buys − sells, ₹Cr). Filing momentum = bullish − bearish filings; Buzz = news+social sentiment. Curate peers in the company admin.
- 2026-06-17FilingLupin Limited has informed the Exchange regarding a press release dated June 17, 2026, titled "Lupin Launches Press Release
- 2026-06-08FilingLupin Limited has informed the Exchange regarding a press release dated Jun 08, 2026, titled "Lupin CollaboratPress Release
- 2025-10-14BlockSELL · ₹11.6 CrGOLDMAN SACHS (SINGAPORE) PTE - ODI
- 2025-10-14BlockBUY · ₹11.6 CrGOLDMAN SACHS BANK EUROPE SE - ODI
- 2025-10-13BlockSELL · ₹16.2 CrGOLDMAN SACHS (SINGAPORE) PTE - ODI
- 2025-10-13BlockBUY · ₹16.2 CrGOLDMAN SACHS BANK EUROPE SE - ODI
- 2025-07-25ActionDividend - Rs 12 Per ShareDividend
- 2024-07-16ActionDividend - Rs 8 Per ShareDividend
Merged from deals, filings, corporate actions and news — newest first. Compact rolls each day up to net flow + counts. Scope with the range above.
Filings that matter
- 2Press ReleaseNeutral
a press release dated June 17, 2026, titled "Lupin Launches Azilsartan Medoxomil Tablets in the United States".
Source PDF → - 2Press ReleaseNeutral
a press release dated Jun 08, 2026, titled "Lupin Collaborates with ERN for Luforbec® (beclometasone/formoterol) pMDI Launch in Spain".
Source PDF →
4 deals · 2025-10-13 → 2025-10-14
| Date | Counterparty | Type | Side | Value |
|---|---|---|---|---|
| 2025-10-14 | GOLDMAN SACHS (SINGAPORE) PTE - ODI | HNI / other | SELL | ₹11.6 Cr |
| 2025-10-14 | GOLDMAN SACHS BANK EUROPE SE - ODI | HNI / other | BUY | ₹11.6 Cr |
| 2025-10-13 | GOLDMAN SACHS (SINGAPORE) PTE - ODI | HNI / other | SELL | ₹16.2 Cr |
| 2025-10-13 | GOLDMAN SACHS BANK EUROPE SE - ODI | HNI / other | BUY | ₹16.2 Cr |
4 deals in the selected window — corporate actions are scoped to the same period. ~2 years of history available.
News & chatter on LUPIN
RSS News
0No recent news.
Google News RSS — links open the source.
Investdesk
0No articles yet.
Our coverage.
No Reddit chatter.
r/ posts mentioning the company.
Twitter / X
0No posts.
Posts mentioning the company.